{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:52:57Z","timestamp":1764510777988,"version":"3.40.5"},"reference-count":29,"publisher":"Informa UK Limited","issue":"13","funder":[{"name":"Blueprint Medicines"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.2217\/fon-2021-1509","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T09:20:32Z","timestamp":1643966432000},"page":"1583-1594","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Indirect Treatment Comparisons of Avapritinib Versus Midostaurin for Patients with Advanced Systemic Mastocytosis"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0649-5214","authenticated-orcid":false,"given":"Hollie","family":"Pilkington","sequence":"first","affiliation":[{"name":"BresMed Health Solutions, Manchester,\rM2 1DH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3380-4411","authenticated-orcid":false,"given":"Sarah","family":"Smith","sequence":"additional","affiliation":[{"name":"BresMed Health Solutions, Manchester,\rM2 1DH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Roskell","sequence":"additional","affiliation":[{"name":"BresMed Health Solutions, Manchester,\rM2 1DH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Iannazzo","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Zug, 6300, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015545"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25371"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205237"},{"key":"e_1_3_6_6_1","unstructured":"US Food and Drug Administration . Rydapt: highlights of prescribing information (2017). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/207997s008lbledt.pdf"},{"key":"e_1_3_6_7_1","unstructured":"Novartis . Rydapt: summary of product characteristics (2017). www.medicines.org.uk\/emc\/product\/9134\/smpc"},{"key":"e_1_3_6_8_1","unstructured":"US Food and Drug Administration . Avyakit: highlights of prescribing information (2020). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212608s000lbl.pdf"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao1690"},{"key":"e_1_3_6_10_1","unstructured":"European Medicines Agency: Committee for medicinal products for human use (CHMP) . Draft agenda for the meeting on 21\u201324 June 2021 (2021). www.ema.europa.eu\/en\/documents\/agenda\/agenda-chmp-agenda-21-24-june-2021-meeting_en.pdf"},{"key":"e_1_3_6_11_1","unstructured":"ClinicalTrials.gov . (EXPLORER) Study of BLU-285 in patients with advanced systemic mastocytosis (AdvSM) and relapsed or refractory myeloid malignancies(2021).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02561988"},{"key":"e_1_3_6_12_1","unstructured":"ClinicalTrials.gov . (PATHFINDER) Study to evaluate efficacy and safety of avapritinib (BLU-285) a selective KIT mutation-targeted tyrosine kinase inhibitor in patients with advanced systemic mastocytosis(2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03580655"},{"key":"e_1_3_6_13_1","unstructured":"ClinicalTrials.gov . Efficacy and safety of midostaurin in patients with aggressive systemic mastocytosis or mast cell leukemia(2018).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00782067"},{"key":"e_1_3_6_14_1","unstructured":"ClinicalTrials.gov . Phase 2 midostaurin in aggressive systemic mastocytosis and mast cell leukemia(2018).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00233454"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00168-6"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01807.x"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062983"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-458521"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.127"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"e_1_3_6_22_1","unstructured":"NICE Decision Support Unit . NICE DSU TSD 18: methods for population-adjusted indirect comparisons in submissions to NICE(2016).http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2018\/08\/Population-adjustment-TSD-FINAL-ref-rerun.pdf"},{"key":"e_1_3_6_23_1","unstructured":"R: a language and environment for statistical computing. R Foundation for Statistical Computingwww.r-project.org\/"},{"key":"e_1_3_6_24_1","unstructured":"MAIC: R package https:\/\/roche.github.io\/MAIC\/"},{"key":"e_1_3_6_25_1","unstructured":"survminer: drawing survival curves using \u2018ggplot2\u2019 https:\/\/cran.r-project.org\/web\/packages\/survminer\/survminer.pdf"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01538-9"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01539-8"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513098"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.234"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0222"},{"key":"e_1_3_6_31_1","unstructured":"National Institute for Health and Care Excellence . Midostaurin for treating advanced systemic mastocytosis: final appraisal document (2021). www.nice.org.uk\/guidance\/ta728\/documents\/final-appraisal-determination-document"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-1509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:58Z","timestamp":1719125158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-1509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":29,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.2217\/fon-2021-1509"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-1509","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}